Development of matrix metalloproteinase inhibitors in cancer therapy.
The matrix metalloproteinases represent an attractive target for cancer treatment, and a number of matrix metalloproteinase inhibitors are undergoing clinical trials. The results of these studies will establish whether any of these compounds are therapeutically useful. Independent of the conclusions from the first generation of studies, the field of matrix metalloproteinase inhibitors remains attractive for creative and innovative research. In the future, the development of novel, less toxic, and more effective matrix metalloproteinase inhibitors, and the combination of conventional agents with these novel anticancer agents will constitute the main focus of research efforts.
Purcell
W Thomas
WT
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Division of Medical Oncology, Baltimore, MD 21231-2410, USA.
Rudek
Michelle A
MA
Hidalgo
Manuel
M
D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000627:therapeutic use; D015195:Drug Design; D004354:Drug Screening Assays, Antitumor; D005544:Forecasting; D006801:Humans; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000502:physiology; D009361:Neoplasm Invasiveness; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000502:physiology; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000201:enzymology; D011480:Protease Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D013754:Tetracyclines / Q000627:therapeutic use
D004164:Diphosphonates; D061965:Matrix Metalloproteinase Inhibitors; D009363:Neoplasm Proteins; D011480:Protease Inhibitors; D013754:Tetracyclines; D020782:Matrix Metalloproteinases